Unique and joint associations of polygenic risk for major depression and opioid use disorder with endogenous opioid system function.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
31
10
2021
accepted:
06
04
2022
revised:
30
03
2022
pubmed:
12
5
2022
medline:
16
8
2022
entrez:
11
5
2022
Statut:
ppublish
Résumé
Major depressive disorder (MDD) and opioid use disorder (OUD) are common, potentially fatal, polygenic disorders that are moderately heritable and often co-occur. We examined the unique and shared associations of polygenic risk scores (PRS) for these disorders with µ-opioid receptor (MOR) concentration and endogenous opioid response during a stressful stimulus. Participants were 144 healthy European-ancestry (EA) subjects (88 females) who underwent MOR quantification scans with [
Identifiants
pubmed: 35545664
doi: 10.1038/s41386-022-01325-1
pii: 10.1038/s41386-022-01325-1
pmc: PMC9372136
doi:
Substances chimiques
Analgesics, Opioid
0
Opioid Peptides
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1784-1790Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIDA NIH HHS
ID : K23 DA038726
Pays : United States
Organisme : NIAAA NIH HHS
ID : K01 AA024167
Pays : United States
Organisme : NIAAA NIH HHS
ID : K01 AA028292
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH123619
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Références
Martins SS, Fenton MC, Keyes KM, Blanco C, Zhu H, Storr CL. Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions. Psychol Med. 2012;42:1261–72.
pubmed: 21999943
doi: 10.1017/S0033291711002145
Fink DS, Hu R, Cerdá M, Keyes KM, Marshall BDL, Galea S, et al. Patterns of major depression and nonmedical use of prescription opioids in the United States. Drug Alcohol Depend. 2015;153:258–64.
pubmed: 26026492
pmcid: 4509797
doi: 10.1016/j.drugalcdep.2015.05.010
SAMHSA. Results from the 2019 national survey on drug use and health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2020.
Rosoff DB, Smith GD, Lohoff FW. Prescription opioid use and risk for major depressive disorder and anxiety and stress-related disorders: A multivariable Mendelian randomization analysis. JAMA Psychiatry. 2021;78:151–60.
pubmed: 33175090
doi: 10.1001/jamapsychiatry.2020.3554
Zubieta J-K, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA, et al. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry. 2003;60:1145–53.
pubmed: 14609890
doi: 10.1001/archpsyc.60.11.1145
Peciña M, Karp JF, Mathew S, Todtenkopf MS, Ehrich EW, Zubieta J-K. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry. 2019;24:576–87.
pubmed: 29955162
doi: 10.1038/s41380-018-0117-2
Gabilondo AM, Meana JJ, García-Sevilla JA. Increased density of mu-opioid receptors in the postmortem brain of suicide victims. Brain Res. 1995;682:245–50.
pubmed: 7552322
doi: 10.1016/0006-8993(95)00333-L
Escribá PV, Ozaita A, García-Sevilla JA. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology. 2004;29:1512–21.
pubmed: 15199368
doi: 10.1038/sj.npp.1300459
Darcq E, Kieffer BL. Opioid receptors: drivers to addiction? Nat Rev Neurosci. 2018;19:499–514.
pubmed: 29934561
doi: 10.1038/s41583-018-0028-x
Howard DM, Adams MJ, Clarke T-K, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22:343–52.
pubmed: 30718901
pmcid: 6522363
doi: 10.1038/s41593-018-0326-7
Crist RC, Reiner BC, Berrettini WH. A review of opioid addiction genetics. Curr Opin Psychol 2019;27:31–35.
pubmed: 30118972
doi: 10.1016/j.copsyc.2018.07.014
Zhou H, Rentsch CT, Cheng Z, Kember RL, Nunez YZ, Sherva RM, et al. Association of OPRM1 functional coding variant with opioid use disorder: a genome-wide association study. JAMA Psychiatry. 2020. https://doi.org/10.1001/jamapsychiatry.2020.1206
Anderson JS, Shade J, DiBlasi E, Shabalin AA, Docherty AR. Polygenic risk scoring and prediction of mental health outcomes. Curr Opin Psychol. 2019;27:77–81.
pubmed: 30339992
doi: 10.1016/j.copsyc.2018.09.002
Erbs E, Faget L, Scherrer G, Matifas A, Filliol D, Vonesch JL, et al. A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct Funct. 2015;220:677–702.
pubmed: 24623156
doi: 10.1007/s00429-014-0717-9
Charbogne P, Kieffer BL, Befort K. 15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse. Neuropharmacology. 2014;76 Pt B:204–17.
pubmed: 24035914
doi: 10.1016/j.neuropharm.2013.08.028
Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Walker SJ, et al. It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder. Mol Psychiatry. 2015;20:193–200.
pubmed: 25600108
pmcid: 4469367
doi: 10.1038/mp.2014.185
Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA. 1997;94:1544–9.
pubmed: 9037090
pmcid: 19828
doi: 10.1073/pnas.94.4.1544
Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 1996;383:819–23.
pubmed: 8893006
doi: 10.1038/383819a0
Weerts EM, McCaul ME, Kuwabara H, Yang X, Xu X, Dannals RF, et al. Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects. Int J Neuropsychopharmacol. 2013;16:47–53.
pubmed: 22397905
doi: 10.1017/S146114571200017X
Peciña M, Love T, Stohler CS, Goldman D, Zubieta J-K. Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures. Neuropsychopharmacology. 2015;40:957–65.
pubmed: 25308352
doi: 10.1038/npp.2014.272
Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C, et al. Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci USA. 2011;108:9268–73.
pubmed: 21576462
pmcid: 3107291
doi: 10.1073/pnas.1018699108
Zhou Z, Zhu G, Hariri AR, Enoch MA, Scott D, Sinha R, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature. 2008;452:997–1001.
pubmed: 18385673
pmcid: 2715959
doi: 10.1038/nature06858
Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science. 2001;293:311–5.
pubmed: 11452128
doi: 10.1126/science.1060952
Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry. 1999;156:842–8.
pubmed: 10360121
doi: 10.1176/ajp.156.6.842
Zubieta J-K, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, et al. mu-opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci. 2002;22:5100–7.
pubmed: 12077205
pmcid: 6757760
doi: 10.1523/JNEUROSCI.22-12-05100.2002
Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet. 2014;46:1173–86.
pubmed: 25282103
pmcid: 4250049
doi: 10.1038/ng.3097
Zubieta J-K. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci. 2005;25:7754–62.
pubmed: 16120776
pmcid: 6725254
doi: 10.1523/JNEUROSCI.0439-05.2005
Peciña M, Bohnert ASB, Sikora M, Avery ET, Langenecker SA, Mickey BJ, et al. Association between placebo-activated neural systems and antidepressant responses: neurochemistry of placebo effects in major depression. JAMA Psychiatry. 2015;72:1087–94.
pubmed: 26421634
pmcid: 4758856
doi: 10.1001/jamapsychiatry.2015.1335
Zubieta J-K, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240–3.
pubmed: 12595695
doi: 10.1126/science.1078546
Martikainen IK, Pecina M, Love TM, Nuechterlein EB, Cummiford CM, Green CR, et al. Alterations in endogenous opioid functional measures in chronic back pain. J Neurosci. 2013;33:14729–37.
pubmed: 24027273
pmcid: 3771036
doi: 10.1523/JNEUROSCI.1400-13.2013
1000 Genomes Project Consortium, Auton AA, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. Nature. 2015;526:68–74.
doi: 10.1038/nature15393
Stohler CS, Kowalski CJ. Spatial and temporal summation of sensory and affective dimensions of deep somatic pain. Pain. 1999;79:165–73.
pubmed: 10068162
doi: 10.1016/S0304-3959(98)00171-7
Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019;10:1776.
pubmed: 30992449
pmcid: 6467998
doi: 10.1038/s41467-019-09718-5
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57:289–300.
Smith KS, Berridge KC. Opioid limbic circuit for reward: interaction between hedonic hotspots of nucleus accumbens and ventral pallidum. J Neurosci. 2007;27:1594–605.
pubmed: 17301168
pmcid: 6673729
doi: 10.1523/JNEUROSCI.4205-06.2007
Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403–13.
pubmed: 16055761
doi: 10.1176/appi.ajp.162.8.1403
Berridge KC, Kringelbach ML. Towards a neuroscience of well-being: implications of insights from pleasure research. In: Happiness studies book series. Springer Netherlands; 2013. p. 81–100.
Loseth GE, Ellingsen D-M, Leknes S. State-dependent μ-opioid modulation of social motivation. Front Behav Neurosci. 2014;8:430.
pubmed: 25565999
pmcid: 4264475
doi: 10.3389/fnbeh.2014.00430
Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Wang H, et al. Response of the μ-opioid system to social rejection and acceptance. Mol Psychiatry. 2013;18:1211–7.
pubmed: 23958960
pmcid: 3814222
doi: 10.1038/mp.2013.96
Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760–73.
pubmed: 27475769
pmcid: 6135092
doi: 10.1016/S2215-0366(16)00104-8
Volkow ND, Baler RD, Goldstein RZ. Addiction: pulling at the neural threads of social behaviors. Neuron. 2011;69:599–602.
pubmed: 21338873
pmcid: 3188411
doi: 10.1016/j.neuron.2011.01.027
Love TM, Stohler CS, Zubieta J-K. Positron emission tomography measures of endogenous opioid neurotransmission and impulsiveness traits in humans. Arch Gen Psychiatry. 2009;66:1124–34.
pubmed: 19805703
pmcid: 3085183
doi: 10.1001/archgenpsychiatry.2009.134
Salk RH, Hyde JS, Abramson LY. Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms. Psychol Bull. 2017;143:783–822.
pubmed: 28447828
pmcid: 5532074
doi: 10.1037/bul0000102
Jamison RN, Butler SF, Budman SH, Edwards RR, Wasan AD. Gender differences in risk factors for aberrant prescription opioid use. J Pain. 2010;11:312–20.
pubmed: 19944648
doi: 10.1016/j.jpain.2009.07.016
Evans EA, Goff SL, Upchurch DM, Grella CE. Childhood adversity and mental health comorbidity in men and women with opioid use disorders. Addict Behav. 2020;102:106149.
pubmed: 31855783
doi: 10.1016/j.addbeh.2019.106149
Grella CE, Karno MP, Warda US, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav. 2009;34:498–504.
pubmed: 19232832
pmcid: 2708101
doi: 10.1016/j.addbeh.2009.01.002
McHugh RK, Devito EE, Dodd D, Carroll KM, Potter JS, Greenfield SF, et al. Gender differences in a clinical trial for prescription opioid dependence. J Subst Abus Treat. 2013;45:38–43.
doi: 10.1016/j.jsat.2012.12.007
Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, et al. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abus. 2011;37:313–23.
doi: 10.3109/00952990.2011.596982
Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 2004;74:265–72.
pubmed: 15194204
doi: 10.1016/j.drugalcdep.2004.02.001
Kennedy SE, Koeppe RA, Young EA, Zubieta J-K. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63:1199–208.
pubmed: 17088500
doi: 10.1001/archpsyc.63.11.1199
Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. Neuropsychopharmacology. 2018;43:2514–20.
pubmed: 30250308
pmcid: 6224460
doi: 10.1038/s41386-018-0225-3